Certain breast CA patients benefit from adjuvant capecitabine

June 1, 2017

(HealthDay)—Capecitabine (Xeloda) can extend the lives of patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have residual invasive disease after receipt of neoadjuvant chemotherapy, according to a study published in the June 1 issue of the New England Journal of Medicine.

The new trial focused on 910 women with HER2-negative residual invasive after neoadjuvant chemotherapy. Participants received standard post-surgical treatment either with capecitabine or without (the control group).

The researchers found that capecitabine was associated with a reduced risk of relapse or death (30 percent over five years). At that point, 74.1 percent were still alive and recurrence-free, versus 67.6 percent of women in the control group. Five years later, 89.2 percent of capecitabine patients were still alive, compared with 83.6 percent of control patients. Among women with , 78.8 percent of capecitabine patients were alive after five years, compared with 70.3 percent of control patients.

"After standard containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing," the authors conclude.

Explore further: Capecitabine improved outcomes for breast cancer patients with disease after presurgery chemo

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Capecitabine improved outcomes for breast cancer patients with disease after presurgery chemo

December 9, 2015
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X ...

Capecitabine monotherapy does not improve survival in elderly patients with early-stage breast cancer

December 12, 2014
In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, the chemotherapy capecitabine, which causes fewer side effects than the standard chemotherapy ...

Study finds greater potential benefit in overall survival for eribulin compared with capecitabine

June 12, 2013
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, ...

Axillary pCR linked to improved breast cancer survival

January 5, 2016
(HealthDay)—For women with breast cancer treated with primary systemic chemotherapy (PST), achieving axillary pathologic complete response (pCR) is associated with improved survival, according to a study published online ...

Study compares standard against newer treatment in women whose breast cancer has spread

December 7, 2012
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, ...

Neratinib active in HER2-positive, HR-negative breast cancer

July 7, 2016
(HealthDay)—Neratinib and veliparib-carboplatin appear to be effective in women with specific subtypes of breast cancer, according to two studies published online July 6 in The New England Journal of Medicine.

Recommended for you

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

Understanding epilepsy in pediatric tumors

September 20, 2018
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain cancer has not been elucidated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.